Geneoscopy is developing a noninvasive, stool-based, preventive screening test to diagnose and treat colorectal cancer (CRC) in high-risk individuals with a methodology that is more accurate than a colonoscopy.

Geneoscopy Inc. is a life sciences company focused on the development of diagnostic tests for gastrointestinal health. Geneoscopy’s lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas.

This device was awarded Breakthrough Device Designation from the US FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Indicative of its breakthrough status, preliminary trials suggest that the diagnostic can detect these lesions at a higher rate than all existing noninvasive screening tests.

For more information, visit Geneoscopy or follow their updates on:

Geneoscopy Starts Human Colorectal Cancer Screening Trial

Geneoscopy Gets Key FDA Designation, Hires New Exec

It Takes a Village (and Universities Directly Engaging the Startup Ecosystem) to Retain Talent in St. Louis

Diagnostics Tool Developer Secures $1M in Funding to Detect GI Disease

Geneoscopy Raises $1 million

5 St. Louis entrepreneurs named Pipeline fellows

Strayos and Geneoscopy Win Wash U Global Impact Awards

The Agile Mission of BioGenerator’s Grants Program

Arcus Awards

Finalists Announced for 4th Annual St. Louis Regional Chamber Arcus Awards

Accelerate St. Louis Awards $120,000 in Prizes at Startup Connection 2016

Accelerate St. Louis Challenge 2015

Accelerate St. Louis Contest Finalists Announced, Winners to Be Announced During Global Entrepreneurship Week

Arch Grants Announces Summer 2016 Global Startup Competition Recipients

Greetabl Takes Top Prize at First TechCrunch Pitch-Off